Congenital Adrenal Hyperplasia Medical Services in China

Congenital Adrenal Hyperplasia (CAH) is a group of autosomal recessive genetic disorders characterized by impaired cortisol biosynthesis due to enzymatic defects in the adrenal steroidogenesis pathway—most commonly 21-hydroxylase deficiency (accounting for >90% of cases). This enzymatic blockade leads to cortisol deficiency, compensatory adrenocorticotropic hormone (ACTH) overproduction, and adrenal hyperplasia. Concurrently, precursor accumulation shunts into androgen biosynthesis, resulting in prenatal or postnatal androgen excess. In classic CAH, severe enzyme deficiency manifests in infancy with life-threatening salt-wasting crises (hyponatremia, hyperkalemia, hypovolemic shock) or virilization in genetically female infants (ambiguous genitalia), while non-classic CAH presents later with premature pubarche, hirsutism, oligomenorrhea, infertility, or acne—often misdiagnosed as PCOS. Epidemiologically, classic CAH occurs in approximately 1:15,000 live births globally, with higher prevalence in certain founder populations (e.g., Ashkenazi Jews, Yupik Alaskans); non-classic CAH is more common (~1:200–1:1,000 in some ethnic groups). Risk factors include consanguinity and family history; carrier frequency is ~1:50–1:70 in general populations. From a reproductive medicine perspective, CAH profoundly impacts fertility: women may experience anovulation, chronic anovulatory cycles, and ovarian hyperandrogenism leading to subfertility or recurrent pregnancy loss; men may develop testicular adrenal rest tumors (TARTs), oligospermia, or reduced testosterone. Psychosocial burden includes gender identity concerns in severely virilized females, anxiety around fertility, lifelong medication adherence challenges, and stigma related to hirsutism or menstrual dysfunction. Quality of life is further compromised by chronic fatigue, metabolic comorbidities (insulin resistance, obesity), and increased risk of cardiovascular disease with suboptimal glucocorticoid replacement. Early diagnosis via newborn screening (17-OHP assay), timely hormonal replacement (hydrocortisone, fludrocortisone), and multidisciplinary care—including endocrinology, reproductive endocrinology, psychology, and genetics—are essential to normalize growth, preserve fertility, prevent adrenal crises, and support psychosocial well-being across the lifespan.

Congenital Adrenal Hyperplasia (CAH) is an autosomal recessive disorder characterized by enzymatic defects in cortisol biosynthesis, most commonly due to 21-hydroxylase deficiency (95% of cases). In the Department of Reproductive Medicine, CAH management focuses on optimizing hormonal homeostasis, preserving fertility potential, preventing virilization or undervirilization, and supporting psychosocial well-being—particularly in individuals with disorders of sex development (DSD), such as 46,XX females with prenatal androgen excess or 46,XY males with atypical genital phenotypes. Treatment is lifelong, multidisciplinary, and individualized according to genotype, phenotype, age at diagnosis, and reproductive goals.

Conservative treatment forms the cornerstone of CAH management and emphasizes continuous endocrine surveillance and lifestyle integration. It includes regular monitoring of serum 17-hydroxyprogesterone (17-OHP), androstenedione, testosterone, renin activity, electrolytes, growth velocity, bone age, and bone mineral density. For women of reproductive age, assessment of ovarian reserve (AMH, AFC), menstrual cyclicity, and pelvic ultrasound for adrenal rest tumors or polycystic ovarian morphology is essential. Conservative strategies also involve nutritional counseling to mitigate metabolic risks associated with chronic glucocorticoid use—including insulin resistance, central adiposity, and dyslipidemia—as well as psychological support to address body image concerns, gender identity development, and sexual health. Fertility counseling should begin in adolescence: while spontaneous conception is possible in classic CAH, especially with optimized control, subfertility is common due to chronic hyperandrogenism, anovulation, and hypothalamic-pituitary-ovarian axis dysregulation. In men, testicular adrenal rest tumors (TARTs) may impair spermatogenesis; therefore, annual scrotal ultrasound and semen analysis are recommended starting at puberty.

Pharmacotherapy remains the primary medical intervention. Glucocorticoid replacement—typically hydrocortisone (10–15 mg/m²/day in children, 15–25 mg/day in adults, divided into two or three doses)—is titrated to suppress adrenal androgen overproduction while avoiding Cushingoid side effects. In adults, longer-acting agents like prednisolone or dexamethasone may be considered for improved adherence, though dexamethasone carries higher risks of osteoporosis and metabolic complications and is avoided in pregnancy unless strictly indicated for prenatal therapy. Mineralocorticoid replacement (fludrocortisone 0.05–0.2 mg/day) is mandatory in salt-wasting forms to maintain sodium balance and suppress renin. During illness, injury, or surgery, patients require stress-dose glucocorticoids (e.g., hydrocortisone 50–100 mg IV/IM) to prevent adrenal crisis—a life-threatening emergency. For women with persistent hyperandrogenism despite optimal glucocorticoid dosing, adjunctive anti-androgens (e.g., spironolactone 50–200 mg/day) or combined oral contraceptives may be used cautiously, recognizing their limited evidence base in CAH and potential interference with adrenal hormone monitoring. Newer agents under investigation include CRH receptor antagonists and selective 11β-HSD1 inhibitors, though none are yet standard-of-care.

Surgical intervention is reserved for specific indications and always follows comprehensive multidisciplinary evaluation—including endocrinology, reproductive medicine, urology, psychology, and ethics consultation. In 46,XX infants with severe virilization (Prader III–V), feminizing genitoplasty—comprising clitoral reduction (notectomy or recession) and vaginoplasty—may be performed in early infancy (3–12 months) when tissue vascularity and healing capacity are optimal. However, current international consensus strongly advocates deferring irreversible surgery until the patient can participate meaningfully in decision-making, except in cases of urinary obstruction or recurrent infection. In adolescents and adults, revisional surgery may address functional concerns (e.g., vaginal stenosis, dyspareunia) or cosmetic dissatisfaction. For males with TARTs causing pain, obstruction, or progressive testicular damage, surgical excision or debulking may be indicated, though fertility preservation via sperm retrieval prior to intervention is prioritized. Laparoscopic adrenalectomy is rarely performed and only in refractory, unilateral, non-metastatic adrenal cortical neoplasms misdiagnosed initially as CAH-related hyperplasia.

Treatment advantages in China reflect rapid advancements in integrated care delivery. Major tertiary hospitals—especially those affiliated with universities in Beijing, Shanghai, Guangzhou, and Chengdu—offer centralized CAH registries linked to national newborn screening programs, enabling diagnosis within days of birth. Genotype-phenotype correlation is routinely performed using next-generation sequencing panels covering all known CAH-associated genes (CYP21A2, CYP11B1, HSD3B2, etc.), facilitating prognostication and family counseling. Reproductive Medicine Departments collaborate closely with Assisted Reproductive Technology (ART) centers: ovulation induction with low-dose gonadotropins or letrozole is increasingly successful in women with CAH, and ICSI with preimplantation genetic testing (PGT-M) is available for couples seeking to avoid transmission. Moreover, China’s National Health Insurance now covers lifelong hydrocortisone and fludrocortisone for confirmed CAH, significantly improving medication adherence. Telemedicine platforms enable longitudinal follow-up for rural patients, and standardized clinical pathways—endorsed by the Chinese Society of Endocrinology and the Chinese Medical Association of Reproductive Medicine—ensure evidence-based, equitable care across regions.

Recovery and long-term self-management advice emphasize empowerment through education. Patients and families should receive written emergency action plans detailing sick-day rules, injectable hydrocortisone administration, and when to seek urgent care. Annual dual-energy X-ray absorptiometry (DXA) scans are advised after age 18 to monitor bone health. Regular gynecologic evaluation—including transvaginal ultrasound and cervical cytology—is critical for women, particularly those with a history of vaginal surgery or chronic anovulation. Men should undergo annual testicular ultrasound and hormonal profiling. Psychological resilience is fostered through peer support networks (e.g., the China CAH Alliance) and access to certified sexologists and reproductive counselors. Pregnancy requires preconception optimization: glucocorticoid doses are adjusted to physiological needs, and close maternal-fetal monitoring mitigates risks of preeclampsia, gestational diabetes, and fetal adrenal suppression. With consistent, expert-guided care, individuals with CAH achieve normal life expectancy, healthy pregnancies, and fulfilling reproductive lives—underscoring that optimal outcomes depend not solely on pharmacotherapy, but on sustained, compassionate, and patient-centered reproductive medicine partnership.